Amlodipine + OlmesartanThird Party Manufacturing in India

Amlodipine and Olmesartan is a fixed-dose antihypertensive combination that achieves potent blood pressure reduction through complementary blockade of two distinct pathways involved in vascular resistance regulation, providing synergistic efficacy and improved tolerability compared to either component used alone.

Amlodipine is a dihydropyridine calcium channel blocker that selectively inhibits the influx of extracellular calcium ions into vascular smooth muscle cells through L-type calcium channels. By binding to the alpha-1 subunit of these voltage-gated channels, amlodipine prevents the calcium-mediated activation of myosin light chain kinase, which is essential for smooth muscle contraction. This inhibition leads to relaxation of arterial smooth muscle, peripheral vasodilation, and reduced systemic vascular resistance. Amlodipine has a gradual onset of action and a long elimination half-life of 30 to 50 hours, providing smooth and consistent 24-hour blood pressure control with once-daily dosing. Its high vascular selectivity minimises negative inotropic effects on the myocardium at therapeutic concentrations.

Olmesartan medoxomil is a prodrug that is rapidly hydrolysed to its active metabolite olmesartan, a potent and selective angiotensin II type 1 receptor blocker. Olmesartan competitively and insurmountably blocks the binding of angiotensin II to the AT1 receptor subtype, which mediates the major cardiovascular effects of the renin-angiotensin system including vasoconstriction, aldosterone secretion, renal sodium reabsorption, sympathetic activation, and vascular smooth muscle proliferation. By blocking angiotensin II at the receptor level rather than inhibiting its formation, olmesartan provides more complete blockade of the RAAS than ACE inhibitors, as it prevents the effects of angiotensin II generated through both ACE-dependent and non-ACE dependent pathways mediated by chymase and other proteases.

Therapeutic Uses

Amlodipine + Olmesartan combination is prescribed for:

• Essential Hypertension: Provides superior blood pressure reduction compared to maximum doses of either monotherapy, with response rates exceeding 80 percent in patients with moderate to severe hypertension. The combination is effective across all demographic groups including elderly patients and those with isolated systolic hypertension.
• Hypertension with Metabolic Syndrome: This combination is particularly suitable for patients with metabolic syndrome as neither component adversely affects glucose metabolism or lipid profiles. Olmesartan has been shown to improve insulin sensitivity and reduce markers of oxidative stress and inflammation.
• Hypertension with Chronic Kidney Disease: Olmesartan provides renoprotective effects by reducing intraglomerular hypertension and proteinuria through selective efferent arteriolar dilation, while amlodipine effectively lowers systemic blood pressure without compromising renal perfusion.
• Resistant Hypertension: The amlodipine plus olmesartan combination forms a rational foundation for multi-drug regimens in patients requiring three or more antihypertensive agents.
• Hypertension with Left Ventricular Hypertrophy: Both components contribute to regression of left ventricular hypertrophy through blood pressure reduction and direct antiproliferative effects on cardiac myocytes.
• Hypertension in Diabetic Patients: The combination provides end-organ protection in diabetic patients by combining the antiproteinuric effects of olmesartan with the vasoprotective and anti-atherosclerotic effects of amlodipine.

Why Manufacturers Choose This Combination

The amlodipine plus olmesartan combination represents one of the most effective dual antihypertensive therapies available, combining a calcium channel blocker with an angiotensin receptor blocker. This pairing is recommended by major international hypertension guidelines for first-line combination therapy, particularly in patients with diabetes, metabolic syndrome, or CKD where ARBs have demonstrated additional organ-protective benefits. The oral liquid formulation enables access for patients with dysphagia, including the elderly, and allows flexible dosing through the available strengths. Indian WHO-GMP certified manufacturers producing this combination for the domestic and export market benefit from the strong patent-expired status of both molecules, well-established API supply chains with multiple domestic manufacturers, and consistent demand from both prescription and hospital channels. This makes Amlodipine + Olmesartan a strategically important product for third party manufacturing in India targeting the large and growing antihypertensive market.